| Title |
Regimen |
Criteria |
| ABC-02 |
Gemcitabine, alone or in combination with cisplatin |
In patients with advanced or metastatic cholangiocarcinomas and other biliary tract tumours |
| ESPAC-3 (v2) |
Gemcitabine versus 5FU/FA |
Adjuvant chemotherapy in resectable pancreatic cancer |
| Hep-1 |
Doxorubicin chemoembolisation versus systemic doxorubicin |
In patients with unresectable, advanced hepatocellular carcinoma |
| BILCAP |
Capecitabine compared to expectant treatment alone |
Adjuvant chemotherapy following surgery for biliary tract cancer |
| AG013736 |
Gemcitabine plus/minus agent AG013736 |
For patients with locally advanced and/or metastatic pancreatic cancer |
| BAY 43-9006 |
Doxorubicin plus/minus Sorafenib(BAY 43-9006) |
Patients with advanced HCC (unresectable and/or metastatic), with histological or cytological conformation. |
